Clinical Trials

DermatologicGenitourinaryThoracic

1,800 enrolled

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT03262454 2022-04-06

Atezolizumab

35 enrolled

Small Cell Lung Cancer Recurrent

NCT05034055 2021-09-05

SKYROCKET

45 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04465942 2021-08-23

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

300 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04696939 2021-01-06

Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients

100 enrolled

Small Cell Lung Carcinoma

NCT04136470 2020-08-10

BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics

130 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms

NCT04145232 2020-08-10

AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.

30 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

40 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

4,724 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03647956 2019-04-17

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03616691 2018-08-06

Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC

46 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03228368 2017-07-24

The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients

10 enrolled